PATRIOT:评估特异性共济失调毛细血管扩张及Rad3相关(ATR)抑制剂AZD6738单药及联合姑息性放疗治疗实体瘤患者耐受性、安全性和生物学效应的I期研究
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-06-08
PATRIOT是一项I期研究,评估ATR抑制剂AZD6738单药及联合姑息性放疗的耐受性、安全性和生物学效应;本文描述该研究方案,研究于2014年启动,目前正在招募,包括药物和放疗的剂量递增及扩展队列。
要点
- PATRIOT为I期研究,评估AZD6738单药及联合姑息性放疗。
- 研究包括药物和放疗的剂量递增及扩展队列。
- 研究于2014年启动,目前正在招募。
核心结论
- 本文描述PATRIOT研究方案,该研究评估AZD6738单药及联合姑息性放疗的耐受性、安全性和生物学效应。
研究设计与样本
- I期研究,包括药物和放疗的剂量递增及扩展队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。
引用
- Dillon MT, Boylan Z, Smith D, et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin Transl Radiat Oncol. 2018. PMID: 30073210. doi:10.1016/j.ctro.2018.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。